Evidence map›Paper›PMID 38982182›Full record

ArticleCommunications biology2024

A-to-I RNA co-editing predicts clinical outcomes and is associated with immune cells infiltration in hepatocellular carcinoma.

Juan Chen, Cheng-Hui Zhang, Tao Tao, Xian Zhang, Yan Lin, Fang-Bin Wang, Hui-Fang Liu, Jian Liu

Abstract read
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Clinical applications of oligonucleotides for cancer therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Juan Chen *School of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, China.ORCID 0009-0000-3141-8491
Cheng-Hui Zhang *School of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, China.
Tao TaoSchool of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, China.
Xian ZhangSchool of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, China.
Yan LinSchool of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, China.
Fang-Bin WangSchool of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, China.
Hui-Fang LiuDepartment of Endocrinology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430014, Hubei, China. Liu_HF91@163.com.ORCID 0000-0003-0675-0753
Jian LiuSchool of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, China. liujian509@hfut.edu.cn.ORCID 0000-0002-3220-1240

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32070757Natural Science Foundation of Anhui Province (Anhui Provincial Natural Science Foundation) 1908085QC98
6 · The paper itself

Abstract

Aberrant RNA editing has emerged as a pivotal factor in the pathogenesis of hepatocellular carcinoma (HCC), but the impact of RNA co-editing within HCC remains underexplored. We used a multi-step algorithm to construct an RNA co-editing network in HCC, and found that HCC-related RNA editings are predominantly centralized within the network. Furthermore, five pairs of risk RNA co-editing events were significantly correlated with the overall survival in HCC. Based on presence of risk RNA co-editings resulted in the categorization of HCC patients into high-risk and low-risk groups. Disparities in immune cell infiltrations were observed between the two groups, with the high-risk group exhibiting a greater abundance of exhausted T cells. Additionally, seven genes associated with risk RNA co-editing pairs were identified, whose expression effectively differentiates HCC tumor samples from normal ones. Our research offers an innovative perspective on the etiology and potential therapeutics for HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsRNA EditingBiomarkers, TumorGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, Tumor

Identifiers

PMID38982182
PMCPMC11233613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.